HDAC6-IN-12 

HDAC6-IN-12 (compound GZ) is a potent HDAC6 inhibitor. HDAC6-IN-12 has anticancer activity through merges into DNA strands causing DNA damage. HDAC6-IN-12 can be used for cancer research^[1].

HDAC6-IN-12 (compound GZ) (72 h) has anti-proliferative activity on tumor cells against HuH-7, HeLa, MDA-MB-231, SKOV3, A549, PANC-1, HCT-116, SGC7901 and 4T1 cells with IC₅₀ values of 0.12 μM, 0.43 μM, 0.14 μM, 0.62 μM, 0.14 μM, 1.08 μM, 0.30 μM, 3.70 μM and 0.66 μM, respectively^[1].
HDAC6-IN-12 (compound GZ) (0-3 μM; 24 h; MBA-MB-231 cells) merges into DNA strands causing DNA damage and increases the level of phospho-γ-H2A.X, which is the marker of DNA strand break^[1].
HDAC6-IN-12 (compound GZ) (0-100 μM; 30 min) has major metabolic enzymes including CYP3A2, CYP1A1/2 isoforms^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

HDAC6-IN-12 (compound GZ) (5-10 mg/kg; i.p.; once every three days, for 15 d; bablc female mice) inhibits tumor growth in a dose-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

487.58

C₂₄H₃₉F₂N₃O₅

2803866-44-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li Y, et, al. Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor. Bioorg Med Chem Lett. 2022 Sep 15;72:128881.  [Content Brief]